AB
Alon Ben-Noon
Co-Founder, CEO & Director
Founder · CEOFounder
born 1979comp · $392,000
LOADING SNAPSHOT
Fetching the books…
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin | Source |
|---|---|---|---|---|---|---|
| 2020-12-31 | — | — | — | — | — | 20-F ↗ |
| 2021-12-31 | — | — | $-2.98M | $-3.22M | — | 20-F ↗ |
| 2022-12-31 | — | — | $-10.55M | $-10.49M | — | 20-F ↗ |
| 2023-12-31 | — | — | $-12.05M | $-10.11M | — | 20-F ↗ |
| 2024-12-31 | — | — | $-9.90M | $-10.21M | — | 20-F ↗ |
| 2025-12-31 | — | — | $-11.09M | $-11.13M | — | 20-F ↗ |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.